IP Library Granted Patent US 12,053,439
Granted Patent B2
US 12,053,439 · App. 17/198,102 · Granted Aug 6, 2024

Edible, single-extraction curcuma extracts

Inventors: Indiran Pather (Elk Grove, CA); Tibebe Zewdie Woldemariam (Elk Grove, CA)
Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC
A61K31/12A61K8/35A61K8/9789A61K8/9794A61K36/23A61Q17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,053,439
App. No.
17/198,102
Granted
Aug 6, 2024
Kind
B2
Abstract

Methods of making safe extracts of Curcuma are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.

Claims (43)

1. A method of preparing a formulation acceptable for oral administration having a pharmaceutically acceptable liquid extract of Curcuma , the method comprising:

macerating at least a portion of a Curcuma root for an effective time in an at least substantially non-toxic extraction solvent that includes a component selected from the group consisting of sesame oil, liquid paraffin, glycerin, squalene, cotton seed oil, liquid-grade polyethylene glycol, isopropyl myristate, polysorbate 80, a sorbitan alkanoate, an ethoxylated sorbitan alkanoate, and combinations thereof;

separating the extraction solvent from the macerated Curcuma root to create a liquid extract of Curcuma , the extract including curcumin; and,

incorporating the liquid extract directly into the formulation without removal of the extraction solvent, the carrier having the acute oral toxicity with the LD50 of at least 49,700 mg/kg which is at least substantially less toxic than ethanol.

2. The method of claim 1 , wherein the extraction solvent comprises polyoxyethylene (20) sorbitan monooleate.

3. The method of claim 1 , wherein the extraction solvent comprises isopropyl myristate.

4. The method of claim 1 , wherein the component is sesame oil.

5. The method of claim 1 , wherein the component is cotton seed oil.

6. The method of claim 1 further comprising placing the formulation into a dosage form for treating a tissue of a subject, the treating including inhibiting the onset of, or treating, an infection of the tissue.

7. The method of claim 6 , wherein the tissue is a dermal tissue.

8. The method of claim 6 , wherein the tissue is a mucosal tissue.

9. The method of claim 6 , wherein the tissue is gastrointestinal tissue.

10. The method of claim 1 further comprising placing the formulation into a dosage form for treating a wounded tissue of a subject.

11. The method of claim 10 , wherein the tissue is a dermal tissue.

12. The method of claim 10 , wherein the tissue is a mucosal tissue.

13. The method of claim 10 , wherein the tissue is gastrointestinal tissue.

14. The method of claim 1 further comprising placing the formulation into a dosage form for treating a tissue of a subject, the treating including inhibiting the onset of, or treating, an inflammation of the tissue.

15. The method of claim 14 , wherein the tissue is a dermal tissue.

16. The method of claim 14 , wherein the tissue is a mucosal tissue.

17. The method of claim 16 , wherein the tissue is gastrointestinal tissue.

18. A method of preparing a formulation acceptable for oral administration having a pharmaceutically acceptable emulsion of a liquid extract of Curcuma , the method comprising:

macerating at least a portion of a Curcuma root for an effective time in an at least substantially non-toxic extraction solvent that includes a component selected from the group consisting of sesame oil, liquid paraffin, glycerin, squalene, cotton seed oil, liquid-grade polyethylene glycol, isopropyl myristate, polysorbate 80, a sorbitan alkanoate, an ethoxylated sorbitan alkanoate, and combinations thereof;

separating the extraction solvent from the portion of the macerated Curcuma root to create a liquid extract of Curcuma , the extract including curcumin;

emulsifying the liquid extract; and,

incorporating the emulsified liquid extract directly into the formulation for oral administration without removal of the extraction solvent, the carrier having the acute oral toxicity with the LD50 of at least 49,700 mg/kg which is at least substantially less toxic than ethanol.

19. The method of claim 18 , wherein the extraction solvent comprises polyoxyethylene (20) sorbitan monooleate.

20. The method of claim 18 , wherein the extraction solvent comprises isopropyl myristate.

21. The method of claim 18 , wherein the emulsifying includes adding a pharmaceutically acceptable oil to the liquid extract to create the emulsion of the liquid extract.

22. The method of claim 18 , wherein the emulsifying includes adding an emulgent to the liquid extract to create the emulsion of the liquid extract.

23. The method of claim 21 , wherein the component is sesame oil.

24. The method of claim 21 , wherein the component is cotton seed oil.

25. The method of claim 18 further comprising placing the formulation into a dosage form for treating an infection of a tissue of a subject, the treating including inhibiting the onset of, or treating, an infection of the tissue.

26. The method of claim 25 , wherein the tissue is a dermal tissue.

27. The method of claim 25 , wherein the tissue is a mucosal tissue.

28. The method of claim 25 , wherein the tissue is gastrointestinal tissue.

29. The method of claim 18 further comprising placing the formulation into a dosage form for treating a wounded tissue of a subject.

30. The method of claim 29 , wherein the tissue is a dermal tissue.

31. The method of claim 29 , wherein the tissue is a mucosal tissue.

32. The method of claim 31 , wherein the tissue is gastrointestinal tissue.

33. The method of claim 1 further comprising placing the formulation into a dosage form for treating a tissue of a subject, the treating including inhibiting the onset of, or treating, an infection of the tissue.

34. The method of claim 33 , wherein the tissue is a dermal tissue.

35. The method of claim 33 , wherein the tissue is a mucosal tissue.

36. The method of claim 35 , wherein the tissue is gastrointestinal tissue.

Continuity (4)
Continuation 16264301 · Jan 31, 2019
Continuation 13717677 · Dec 17, 2012
Continuation 13590188 · Aug 21, 2012
Related Publication 20210267913A1 · Sep 2, 2021